More Evidence that Estriol Isn’t Safe
More Evidence that Estriol Isn’t Safe
September 1999; Volume 1: 79
Source: Weiderpass E, et al. Low-potency oestrogen and risk of endometrial cancer: A case-control study. Lancet 1999;353:1824-1828.
Design and Setting: National population-based, case-control study in Sweden.
Subjects: 789 postmenopausal women with endometrial cancer and 3,368 controls (histopathological review reclassified 80 cancer cases as endometrial atypical hyperplasia).
Results: Five years oral use of estriol 1-2 mg/d increased the relative risk of endometrial cancer compared to never-use; the odds ratio was 3.0 for endometrial cancer and 8.3 for atypical endometrial hyperplasia. Ever-use of estriol was associated with a doubling of endometrial cancer risk compared to never-use. The association was stronger for well-differentiated cancers and excess risk was lost quickly on cessation of treatment. Only weak associations were noted for vaginal use of estriol and risk of endometrial neoplasia.
Funding: Research American Cancer Society grant EDT-89; NIH grant RO-1-CA 58427; grant from the Swedish Cancer Society.
Comments: Low-potency estrogen preparations, including estriol, are popular in Sweden (and are usually prescribed without a progestin). In North America, estriol has been promoted by alternative medicine practitioners as a "safe" estrogen that does not cause endometrial proliferation; claims have even been made that it reduces breast cancer risk. These claims were not based on reliable data. (See Alternative Therapies in Women’s Health, June 1999, pp. 51-52.) Although estriol is weaker and shorter-acting than other estrogens used in hormone replacement therapy (HRT), assumptions of harmlessness were premature. This epidemiological study makes it clear that estriol has a significant adverse effect on endometrial neoplasia and should not be used without a progestin.
September 1999; Volume 1: 79
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.